Related Experiment Video
Updated: Jul 11, 2025

Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers
Published on: July 17, 2012
Design, synthesis and biological evaluation of small molecule fluorescent probes targeting EGFR for tumor detection
Depu Song1, Tengli Ding1, Weibin Zhai1
1School of Pharmacy, Henan University, N. Jinming Ave., Kaifeng, Henan, 475004, China. majing@henu.edu.cn.
Abstract:
The epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor that plays a crucial role in cell differentiation and tumor progression, and its overexpression is closely associated with the development and metastasis of multiple cancers. The development of a fluorescent probe capable of targeting EGFR while simultaneously integrating diagnostic and therapeutic functions could have a profound impact on the treatment of related cancers. In this study, we developed a series of EGFR-targeting probes that consisted of an environment-sensitive 1,8-naphthalimide fluorophore, a linker unit and a targeting unit (gefitinib), using a coupling strategy. The synthesized probes were first evaluated for their spectroscopic properties and cytotoxicities against different cell lines, which were selected based on their intrinsic EGFR expression levels. Remarkably, among the probes tested, GP1 showed outstanding environmental sensitivity and exhibited a specific response to tumor cells that overexpress EGFR. Furthermore, the representative probe GP1 was evaluated for its EGFR-specific targeting ability in live-cell fluorescence imaging and in vivo xenograft imaging, as well as its in vivo anti-tumor activity. The results showed that the probe GP1 had excellent EGFR-specific targeting ability, exhibited competitive replacement behavior towards the EGFR inhibitor gefitinib, and demonstrated potent anti-tumor effects in a CT-26 tumor-bearing mouse model. Overall, as a turn-on EGFR targeting fluorescent ligand, GP1 holds immense promise as a valuable tool for tumor detection and treatment.
Insights
Researchers developed a novel fluorescent probe, GP1, that specifically targets and detects cancer cells overexpressing the epidermal growth factor receptor (EGFR). This probe also demonstrates significant anti-tumor activity, offering a promising tool for cancer diagnosis and therapy.
Area of Science:
- Biochemistry
- Molecular Biology
- Medical Imaging
Background:
- Epidermal growth factor receptor (EGFR) overexpression is linked to cancer development and metastasis.
- Targeting EGFR is a key strategy in cancer therapy.
- Developing probes with dual diagnostic and therapeutic functions is crucial for effective cancer treatment.
Purpose of the Study:
- To design and synthesize novel EGFR-targeting fluorescent probes.
- To evaluate the probes' spectroscopic properties, cytotoxicity, and specificity for EGFR-overexpressing cells.
- To assess the probe's efficacy in live-cell imaging, in vivo xenograft imaging, and anti-tumor activity.
Main Methods:
- Synthesis of EGFR-targeting probes using a coupling strategy with a 1,8-naphthalimide fluorophore and gefitinib.
- Spectroscopic analysis and cytotoxicity assays on cell lines with varying EGFR expression.
- Live-cell fluorescence imaging and in vivo xenograft imaging in a mouse model.
- In vivo anti-tumor activity assessment.
Main Results:
- Probe GP1 demonstrated excellent environmental sensitivity and specific response to EGFR-overexpressing tumor cells.
- GP1 exhibited strong EGFR-specific targeting ability in live-cell and in vivo imaging.
- GP1 showed competitive displacement of gefitinib, indicating specific EGFR binding.
- GP1 displayed potent anti-tumor effects in a CT-26 tumor-bearing mouse model.
Conclusions:
- The developed fluorescent probe GP1 is a highly specific EGFR-targeting ligand.
- GP1 functions as a 'turn-on' probe, valuable for real-time tumor detection.
- GP1 shows significant potential as a theranostic tool for cancer diagnosis and treatment.
Related Concept Videos
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against...

